Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like SentreHEART Announces Positive Reimbursement Renewal Decision In Germany February 9, 2017 Vaxil BioTherapeutics To Present At BIO CEO & Investor Conference February 13 – 14, 2017 February 9, 2017 J&J Could Explore Potential $2B Sale of Sterilization Products Division February 19, 2018
Vaxil BioTherapeutics To Present At BIO CEO & Investor Conference February 13 – 14, 2017 February 9, 2017